Results 161 to 170 of about 41,323 (225)

Effectiveness and Safety of a Cross-linked Hyaluronic Acid Plus Mannitol Filler for the Correction of Nasolabial Folds in Chinese Subjects: A Randomized, Blinded, Controlled Study. [PDF]

Aesthet Surg J
Wu Y, Ascher B, Yang Z, Bi H, Li L, Zhao H, Wang H, Zhang J, Luo SK.   +8 more
europepmc   +1 more source

Beyond the Score: Bias Investigations to Improve the Fairness of Board Certification Exams. [PDF]

AEM Educ Train
Joldersma KB, Kraus CK, Gottlieb M.
europepmc   +1 more source

Sex-based differences in outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis of randomised trials. [PDF]

Open Heart
Ferraz-Costa GN, Almeida MJ, Delgado Silva J, Gonçalves L.   +3 more
europepmc   +1 more source

Efficacy and safety of hypofractionated versus conventional radiotherapy in breast cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Talal M, Ahmed MJ, Elsharkawy MM, Al-Ihribat AR, Srour MF, Farhat YZ, Youssef M, Mustafa RB, Wafa MA, Hassan AW, Ahmed Shimal A, Shrebaty O, Moqbel I.   +12 more
europepmc   +1 more source

AlloDerm Versus Cortiva: A Multicenter Pooled Analysis of Clinical and Economic Outcomes in Breast Reconstruction. [PDF]

Plast Reconstr Surg Glob Open
Tanas Y, Harris P, Gasper G, Cato L, Cervantes Valadez S, Rashidi K, Nguyen P, Wang J, Swed S, Zak P.   +9 more
europepmc   +1 more source

Direct oral anticoagulants in portal vein thrombosis in patients with cirrhosis: a systematic review and meta-analysis. [PDF]

Blood Adv
Boccatonda A, Brighenti A, Simion C, Napolitano A, Serra C, Simioni P, Campello E.   +6 more
europepmc   +1 more source

The T Allele of the HNMT C314T Polymorphism Is Associated with a Reduced Risk of Idiopathic Parkinson's Disease in Mexican Patients. [PDF]

Biomedicines
Bueno-Nava A, Díaz-Hernández DK, Paniagua-Pérez R, Carrillo-Mora P, Martínez-Cortez JA, Hernández-Arenas C, León-Hernández SR, Olmos-Hernández A, Verduzco-Mendoza A, Avila-Luna A, Gálvez-Rosas A.   +10 more
europepmc   +1 more source

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma. [PDF]

Cancer Immunol Immunother
Ren Z, Huang Y, Guo Y, Hou MM, Wang W, Kuang M, Hao C, Wang W, Zhang Y, Song T, Dai C, Kuo HT, Bao Z, Zuo Y, Wang L, Zhu F, Fan J.   +16 more
europepmc   +1 more source